Reuters -- European regulators dealt Merck KGaA (MRCG.DE) another blow by sticking with their recommendation against what once was the group’s biggest pipeline hope, multiple sclerosis (MS) pill cladribine.
Reuters -- European regulators dealt Merck KGaA (MRCG.DE) another blow by sticking with their recommendation against what once was the group’s biggest pipeline hope, multiple sclerosis (MS) pill cladribine.
